Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:55PM EDT. Market open.
| Previous Close | 22.53 |
| Open | 21.83 |
| Bid | 22.09 x 200 |
| Ask | 22.32 x 200 |
| Day's Range | 21.63 - 22.26 |
| 52 Week Range | 16.95 - 49.50 |
| Volume | |
| Avg. Volume | 1,537,826 |
| Market Cap | 1.828B |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.67 |
ZacksBeam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
GlobeNewswireBeam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.bea
- GuruFocus.com
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview
Financial Performance and Strategic Developments Amidst Market Challenges
© 2024 Yahoo. All rights reserved.